Efficacy of once-nightly sodium oxybate (FT218) on daytime symptoms in individuals with narcolepsy with or without concomitant alerting agent use: A post hoc analysis from the phase 3 REST-ON trial
Open Access
- 17 September 2024
- journal article
- research article
- Published by Elsevier in Sleep Medicine
- Vol. 124, 209-216
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- Effect of FT218, a Once-Nightly Sodium Oxybate Formulation, on Disrupted Nighttime Sleep in Patients with Narcolepsy: Results from the Randomized Phase III REST-ON TrialCNS Drugs, 2022
- Once-nightly sodium oxybate (FT218) demonstrated improvement of symptoms in a phase 3 randomized clinical trial in patients with narcolepsySLEEP, 2021
- Efficacy and safety of calcium, magnesium, potassium, and sodium oxybates (lower-sodium oxybate [LXB]; JZP-258) in a placebo-controlled, double-blind, randomized withdrawal study in adults with narcolepsy with cataplexySLEEP, 2020
- Effect of sodium oxybate, modafinil, and their combination on disrupted nighttime sleep in narcolepsySleep Medicine, 2017
- The nightly administration of sodium oxybate results in significant reduction in the nocturnal sleep disruption of patients with narcolepsySleep Medicine, 2009
- Narcolepsy with cataplexyThe Lancet, 2007
- Sodium Oxybate Improves Excessive Daytime Sleepiness in NarcolepsySLEEP, 2006
- Further evidence supporting the use of sodium oxybate for the treatment of cataplexy: a double-blind, placebo-controlled study in 228 patientsSleep Medicine, 2005
- Sodium oxybate demonstrates long-term efficacy for the treatment of cataplexy in patients with narcolepsySleep Medicine, 2004
- A New Method for Measuring Daytime Sleepiness: The Epworth Sleepiness ScaleSLEEP, 1991